Detailed Narrative
Capital Allocation Strategy
Royalty Pharma's capital allocation is dynamic, balancing royalty opportunities with stock valuation. In 2025, share repurchases were accelerated early in the year when the stock was deemed attractive, then scaled back as deal activity for royalties increased significantly in the second half. This approach prioritizes long-term returns from new investments while maintaining shareholder returns through buybacks and dividends, with a current bias towards royalty opportunities.
Synthetic Royalty Market Growth
The synthetic royalty market experienced record growth in 2025, with transaction value jumping 50% to $4.7 billion. This funding modality is increasingly recognized at the Board and C-suite levels as a flexible, non-dilutive alternative to traditional debt and equity financing, offering tailored solutions without operational restrictions. Royalty Pharma sees this as a significant growth driver, having pioneered and continuing to lead in this space, with 4 synthetic deals totaling over $2 billion in 2025.
Development Stage Pipeline Potential
Royalty Pharma's development-stage pipeline comprises 20 therapies with estimated combined peak sales of over $43 billion on a non-risk-adjusted basis, potentially translating to over $2.1 billion in peak annual royalties. Upcoming pivotal readouts in the next 24 months, including Revolution Medicine's daraxonrasib for pancreatic cancer and Novartis' pelacarsen for Lp(a), are expected to unlock substantial value and contribute to future top-line growth. The company emphasizes the underappreciated aggregate potential of this pipeline.
China Market Opportunity
Royalty Pharma is actively pursuing opportunities in the Chinese biopharma market, noting a significant increase in out-licensing deals from China to Western multinational companies. The company plans to expand its team and platform locally in China to capitalize on these opportunities, which often involve acquiring royalties from Chinese companies that have licensed products to US/European marketers, ensuring a strong credit risk profile. This strategic focus aims to integrate these earlier-stage assets into their transaction funnel.
Myqorzo and Non-Obstructive HCM
The recent FDA approval and launch of Myqorzo for obstructive hypertrophic cardiomyopathy (HCM) is a significant contributor to Royalty Pharma's top-line growth. While the initial investment thesis was based on the obstructive indication, the company is cautiously optimistic💬 about the ongoing trial for non-obstructive HCM, acknowledging the heterogeneity of the patient population and learning from prior experiences like Camzyos. Data for this potentially large new indication is expected in 2026.
Cystic Fibrosis Franchise Durability
Despite the ongoing conversion to Alyftrek and a lower royalty rate, the cystic fibrosis franchise remains a crucial long-term contributor. Royalty Receipts from the CF franchise grew 7% in 2025. The company anticipates continued strong performance, projecting approximately $800 million in Royalty Receipts from the CF franchise by 2030, even under a downside arbitration scenario. The conversion to Alyftrek has been gradual but steady, consistent with the company's initial expectations.